Pharmacokinetics, pharmacodynamics and safety studies on URB937, a peripherally restricted fatty acid amide hydrolase inhibitor, in rats.

Valentina VozellaFaizy AhmedPaoula ChoobchianCollin B MerrillCristina ZibardiGiorgio TarziaMarco MorAndrea DurantiAndrea TontiniSilvia RivaraDaniele Piomelli

Published in: The Journal of pharmacy and pharmacology (2019)

Pain remains a major unmet medical need. The favourable pharmacokinetic and pharmacodynamic properties of URB937, along with its tolerability, encourage further development studies on this compound.

Keyphrases

fatty acid
case control
chronic pain
healthcare
pain management
open label
clinical trial
double blind
spinal cord
study protocol